… for poor outcomes to first-line therapy (m7–Follicular Lymphoma International Prognostic Index
[m7-… of FL and discuss evolving therapeutic strategies. The biology of follicular lymphoma …

… and immune approaches such as chimeric antigen receptor T cell therapy. The identification
of patients at high risk who require alternative therapies to the current standard of care is a …

… These studies provide support for BR as the primary therapy for indolent follicular lymphoma.
A randomized phase III trial compared initial treatment in previously untreated stage II-IV FL …

… Rituximab alone has been used as the first therapy in patients with indolent lymphoma, with
overall response rates of around 70% and CR rates of over 30% reported.75-77 The most …

… Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with
no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; …

… Phase III trial of consolidation therapy with yttrium-90ibritumomab tiuxetan compared with
no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:…

… Even in the modern era, follicular lymphoma (FL) remains largely an incurable but treatable
… our opinion that the treatment of FL and sequencing of therapy in the R/R setting should be a …

… for synergy in follicular lymphoma-directed therapies. From … to target the CD19 epitope on
follicular lymphoma (FL) cells, … Bispecific antibodies bind both CD20 on the lymphoma cells …

… 2 Day 1) in 513 patients with advanced follicular, indolent, and mantle cell lymphoma [46]. In
… Rituximab alone has been used as the first therapy in patients with indolent lymphoma, with …

… BA Guadagnolo, S Li, D Neuberg, etal: Long-term outcome and mortality trends in early-stage,
grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys …